OBJECTIVES: New antibacterial agents are required for the treatment of infections caused by multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective treatment option or not, is not well established. We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp. METHODS: We searched PubMed for relevant articles and extracted/evaluated the available evidence. RESULTS: We identified 22 microbiological studies reporting data for 2384 Acinetobacter spp. (1906 Acinetobacter baumannii). Susceptibility of at least 90% of the Acinetobacter isolates to tigecycline (with an MIC breakpoint of susceptibility < or =2 mg/L) was noted in 9/18 studies reporting data on MDR Acinetobacter and in 7/15 studies reporting specific data on carbapenem-resistant Acinetobacter. In an additional study reporting data for both resistance categories, adequate susceptibility of Acinetobacter spp. was observed by one (broth microdilution) of the methods employed. The effectiveness of tigecycline for MDR Acinetobacter infections was evaluated in eight identified clinical studies, reporting retrospective data regarding 42 severely ill patients, among whom 31 had respiratory tract infection (in 4 cases with secondary bacteraemia) and 4 had bacteraemia. Tigecycline therapy (in combination with other antibiotics in 28 patients) was effective in 32/42 cases. In three cases, resistance to tigecycline developed during treatment. CONCLUSIONS: Tigecycline showed considerable, though not consistent, antimicrobial activity against MDR (including carbapenem-resistant) Acinetobacter spp. However, data to support its clinical use, particularly for ventilator-associated pneumonia or bacteraemia, caused by these pathogens, are still limited.
OBJECTIVES: New antibacterial agents are required for the treatment of infections caused by multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective treatment option or not, is not well established. We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp. METHODS: We searched PubMed for relevant articles and extracted/evaluated the available evidence. RESULTS: We identified 22 microbiological studies reporting data for 2384 Acinetobacter spp. (1906 Acinetobacter baumannii). Susceptibility of at least 90% of the Acinetobacter isolates to tigecycline (with an MIC breakpoint of susceptibility < or =2 mg/L) was noted in 9/18 studies reporting data on MDR Acinetobacter and in 7/15 studies reporting specific data on carbapenem-resistant Acinetobacter. In an additional study reporting data for both resistance categories, adequate susceptibility of Acinetobacter spp. was observed by one (broth microdilution) of the methods employed. The effectiveness of tigecycline for MDR Acinetobacter infections was evaluated in eight identified clinical studies, reporting retrospective data regarding 42 severely ill patients, among whom 31 had respiratory tract infection (in 4 cases with secondary bacteraemia) and 4 had bacteraemia. Tigecycline therapy (in combination with other antibiotics in 28 patients) was effective in 32/42 cases. In three cases, resistance to tigecycline developed during treatment. CONCLUSIONS:Tigecycline showed considerable, though not consistent, antimicrobial activity against MDR (including carbapenem-resistant) Acinetobacter spp. However, data to support its clinical use, particularly for ventilator-associated pneumonia or bacteraemia, caused by these pathogens, are still limited.
Authors: F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs Journal: Eur J Clin Microbiol Infect Dis Date: 2006-04 Impact factor: 3.267
Authors: J M Cisneros; M J Reyes; J Pachón; B Becerril; F J Caballero; J L García-Garmendía; C Ortiz; A R Cobacho Journal: Clin Infect Dis Date: 1996-06 Impact factor: 9.079
Authors: Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin Journal: Antimicrob Agents Chemother Date: 2007-02-16 Impact factor: 5.191
Authors: Thomas R Fritsche; Helio S Sader; Matthew G Stilwell; Michael J Dowzicky; Ronald N Jones Journal: Diagn Microbiol Infect Dis Date: 2005-07 Impact factor: 2.803
Authors: G Samonis; I P Korbila; S Maraki; I Michailidou; K Z Vardakas; D Kofteridis; D Dimopoulou; V K Gkogkozotou; M E Falagas Journal: Eur J Clin Microbiol Infect Dis Date: 2014-04-15 Impact factor: 3.267